Newly Approved Treatment to Fight the Influenza Virus

  • Home
  • Newly Approved Treatment to Fight the Influenza Virus

With last year’s flu season being one of the worst in many years, it is timely that the Food and Drug Administration (FDA) recently approved the first novel treatment for the flu in almost 20 years.  Having another tool to combat the virus is paramount. Which accounts for the FDA giving it priority review and expediting the approval process.

 



Xofluza, unlike past-approved treatments, requires only one dose versus the traditional 10 doses over a five day period. Both treatments aim to halt flu replication in the human body but target different parts of its cycle. Xofluza blocks an enzyme needed for the virus to replicate earlier in the cycle, and the old treatment halts the replicated virus from leaving its host cell. Both types of drugs help multiple Type A and B strains of the virus.

Xofluza is approved for acute flu patients 12 years of age and older who have been symptomatic for 48 hours or less.

Even with the newly approved treatment, the CDC still recommends a yearly influenza vaccine for everyone six months old and older. Approximately 2 weeks are required for a protective immune response to occur. In addition, not all flu strains are included in the vaccine that is used in a given year and consequently if infected with a strain not included in the vaccine preparation, one is unprotected.

With this flu season already the cause of one death, having another weapon in this fight is vital. Only time will tell if Xofluza will keep curb the death and hospitalized numbers from people with the Influenza virus. 

Also, don't forget to stay connected and join our Quality Lab Group on LinkedIn!
 
 

clinical laboratory, News

About the author

Dr. John Daly



John T. Daly, M.D. is Chief Medical Officer of COLA. Dr. Daly received his MD degree at Weill Cornell University Medical College, performed his internship and residency in Anatomic and Clinical pathology at Duke University Medical Center and a residency in Forensic Pathology at the Office of the Chief Medical Examiner in Chapel Hill, N.C. He is board certified in anatomic, clinical and forensic pathology. Through the course of his career, Dr. Daly has had extensive experience directing and advising laboratories of all sizes including physician office practices, Federal Health Clinics, surgical centers, Community Hospitals and the integrated academic health system clinical laboratories of Duke Medicine. He retired as Director of Laboratories of Duke Medicine, and continues his affiliation as a member of the emeritus staff. He then joined the accreditation organization, COLA, as the Chief Medical Officer. In this role he continues to provide guidance that helps labs improve safety in labs, standardize and streamline operations while achieving CLIA compliance.

Related posts

Advertisement
Advertisement